The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.50
Bid: 18.00
Ask: 19.00
Change: -0.50 (-2.63%)
Spread: 1.00 (5.556%)
Open: 19.00
High: 19.00
Low: 18.50
Prev. Close: 19.00
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Renalytix plc

1 May 2024 08:08

Form 8.5 (EPT/RI) - Renalytix plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Name of exempt principal trader:Investec Bank plc
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeRenalytix plc
(c) Name of the party to the offer with which exempt principal trader is connected:Investec is Joint Broker to Renalytix plc
(d) Date dealing undertaken: 30th April 2024
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” N/A

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid / received (pence)Lowest price per unit paid / received (pence)
Ordinary Shares Purchase 15,000 22 22

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
     

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
    

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
 

Date of disclosure:1st May 2024
Contact name:Jacq Lovis
Telephone number:+44 207 597 4815

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

Date   Source Headline
31st Aug 20217:00 amRNSAppointment of Daniel J. Levangie to Board
26th Aug 20217:00 amRNSPeer reviewed publication
13th Aug 202111:49 amRNSDirector/PDMR Shareholding
6th Aug 20214:42 pmRNSDirector/PDMR Dealing
2nd Aug 202112:00 pmRNSTotal Voting Rights
30th Jul 20214:25 pmRNSDirector/PDMR Dealing
28th Jul 20217:00 amRNSAppointment of Ann Berman to Board of Directors
23rd Jul 202111:30 amRNSDirector/PDMR Shareholding
22nd Jul 20217:00 amRNSVP of Global Quality and Regulatory Appointment
19th Jul 20213:02 pmRNSExercise of Options and TVR
7th Jul 20217:00 amRNSExercise of options, PDMR transaction and TVR
1st Jul 20213:51 pmRNSDirectorate Change
1st Jul 20217:00 amRNSTotal Voting Rights
28th Jun 202111:50 amRNSDirector/PDMR Shareholding
28th Jun 20217:00 amRNSNew data for KidneyIntelX
25th Jun 20215:25 pmRNSDirector/PDMR Dealing
25th Jun 202112:52 pmRNSExercise of options
24th Jun 20212:00 pmRNSChange of name
22nd Jun 20211:25 pmRNSDirector/PDMR Shareholding - Replacement
22nd Jun 202110:57 amRNSDirector/PDMR Shareholding
15th Jun 20217:00 amRNSFinancial Results for Third Quarter of FY 2021
10th Jun 20217:00 amRNSNotice of Results & Change of Auditor
7th Jun 20217:00 amRNSKey new hires to drive commercialization strategy
3rd Jun 20217:00 amRNSUtility Study
25th May 20217:00 amRNSDirector/PDMR Shareholding
21st May 20217:02 amRNSDirector/PDMR Dealing
19th May 20218:00 amRNSPartnership
22nd Apr 20212:06 pmRNSSecond Price Monitoring Extn
22nd Apr 20212:00 pmRNSPrice Monitoring Extension
22nd Apr 202111:05 amRNSSecond Price Monitoring Extn
22nd Apr 202111:00 amRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNS10-year US Government contract award
20th Apr 20217:00 amRNSPositive clinical outcome data for KidneyIntelX
19th Apr 20217:00 amRNSDirector/PDMR Shareholding
14th Apr 20217:00 amRNSExclusive option agreement
8th Apr 20217:00 amRNSClinical Utility Study
6th Apr 20217:00 amRNSClinical findings published in Diabetologia
15th Mar 20217:00 amRNSUpdate on Finalization of MCIT Rule
4th Mar 20216:00 pmRNSIssue of shares, PDMR Dealing and TVR
2nd Mar 20217:02 amRNSFinancial Results for Second Quarter of FY 2021
2nd Mar 20217:00 amRNSHalf-year Report
24th Feb 20217:00 amRNSUniversity of Utah Kidney Health Partnership
23rd Feb 20217:00 amRNSNotice of Results
4th Feb 20217:00 amRNSASN & Renalytix to Co-Host Capital Markets Day
13th Jan 20214:35 pmRNSPrice Monitoring Extension
13th Jan 20217:00 amRNSFinalization of MCIT rule for coverage pathway
5th Jan 20214:41 pmRNSSecond Price Monitoring Extn
5th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSPartnership Between RenalytixAI and DaVita
4th Jan 20217:00 amRNSRENX to present at 39th JP Morgan Healthcare Conf.

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.